Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Insulin (human)
Drug ID BADD_D01159
Description Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mellitus, insulin is a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions.
Indications and Usage Human insulin is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.
Marketing Status approved; investigational
ATC Code A10AB01; A10AC01; A10AD01; A10AE01; A10AF01
DrugBank ID DB00030
KEGG ID D00085
MeSH ID D007328
PubChem ID 118984375
TTD Drug ID D0R6CD
NDC Product Code 0002-8803; 47918-874; 62381-0509; 47918-880; 0338-0126; 0002-8501; 0002-8315; 0002-8715; 0002-8215; 0002-0013; 0002-2510; 47918-878; 47918-891; 0002-8805; 62381-0719; 0002-8824; 0002-0113; 0002-0485; 0002-9307; 62381-0319; 47918-898; 0002-2045; 0002-0096; 0002-0095; 0002-0119; 47918-902
UNII Not Available
Synonyms Insulin | Insulin, Regular | Regular Insulin | Soluble Insulin | Insulin, Soluble | Insulin A Chain | Sodium Insulin | Insulin, Sodium | Novolin | Iletin | Insulin B Chain | Chain, Insulin B
Chemical Information
Molecular Formula C257H383N65O77S6
CAS Registry Number 11061-68-0
SMILES CCC(C)C1C(=O)NC2CSSCC(C(=O)NC(CSSCC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O) NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(NC(=O)C(NC(=O)C(NC(=O)C (NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC2=O)CO)CC(C)C)CC3=CC=C(C=C3)O)CCC(=O) N)CC(C)C)CCC(=O)O)CC(=O)N)CC4=CC=C(C=C4)O)C(=O)NC(CC(=O)N)C(=O)O)C(=O)NCC(=O)NC( CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CC5=CC=CC=C5)C(=O)NC(CC6=CC=CC=C6)C(= O)NC(CC7=CC=C(C=C7)O)C(=O)NC(C(C)O)C(=O)N8CCCC8C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O) O)C(C)C)CC(C)C)CC9=CC=C(C=C9)O)CC(C)C)C)CCC(=O)O)C(C)C)CC(C)C)CC2=CNC=N2)CO)NC(= O)C(CC(C)C)NC(=O)C(CC2=CNC=N2)NC(=O)C(CCC(=O)N)NC(=O)C(CC(=O)N)NC(=O)C(C(C)C)NC( =O)C(CC2=CC=CC=C2)N)C(=O)NC(C(=O)NC(C(=O)N1)CO)C(C)O)NC(=O)C(CCC(=O)N)NC(=O)C(CC C(=O)O)NC(=O)C(C(C)C)NC(=O)C(C(C)CC)NC(=O)CN
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Sputum increased22.02.03.007--Not Available
Swelling08.01.03.015--Not Available
Swollen tongue23.04.01.014; 10.01.05.015; 07.14.02.003--Not Available
Syncope02.11.04.015; 24.06.02.012; 17.02.04.008--
Tachycardia02.03.02.007--Not Available
Tension19.06.02.005--Not Available
Thirst14.03.02.007; 08.01.09.021--Not Available
Throat irritation22.12.03.029; 07.05.05.037--Not Available
Tremor17.01.06.002--
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urinary tract infection20.08.02.001; 11.01.14.004--
Urticaria23.04.02.001; 10.01.06.001--
Vision blurred17.17.01.010; 06.02.06.007--
Visual impairment06.02.10.013--Not Available
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
Wheezing22.03.01.009--
Hypoglycaemic seizure17.12.03.015; 14.06.03.002; 05.06.03.002--Not Available
Localised oedema14.05.06.009; 08.01.07.011; 02.05.04.006--
Lipodystrophy acquired23.07.01.003; 14.08.04.008--Not Available
Balance disorder08.01.03.081; 17.02.02.007--Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Injection site swelling12.07.03.018; 08.02.03.017--Not Available
Tonsillar disorder22.04.05.009--Not Available
Nodule08.03.05.002--Not Available
Affect lability19.04.01.001--Not Available
Infusion site reaction12.07.05.006; 08.02.05.005--Not Available
Neuroglycopenia14.06.03.009; 05.06.03.009; 17.02.05.046--Not Available
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages